Barclays PLC Beam Therapeutics Inc. Transaction History
Barclays PLC
- $353 Billion
- Q1 2025
A detailed history of Barclays PLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 160,046 shares of BEAM stock, worth $2.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
160,046
Previous 278,019
42.43%
Holding current value
$2.7 Million
Previous $6.9 Million
54.66%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding BEAM
# of Institutions
244Shares Held
96.2MCall Options Held
455KPut Options Held
339K-
Farallon Capital Management LLC San Francisco, CA9.93MShares$167 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$164 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.85MShares$149 Million1.24% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$129 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.4.73MShares$79.7 Million0.05% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.19B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...